RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Est. Return
12.81%
1 Year Est. Return
+12.81%
AUM
$791M
AUM Growth
-$79M
(-9.1%)
Holding
105
Top Buys
| 1 | +$15.7M | |
| 2 | +$12.6M | |
| 3 | +$12.1M | |
| 4 |
Cardinal Health
CAH
|
+$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$7.47M |
Top Sells
| 1 | +$19.8M | |
| 2 | +$15.2M | |
| 3 | +$14.9M | |
| 4 |
UnitedHealth
UNH
|
+$14.7M |
| 5 |
McKesson
MCK
|
+$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Immunovant
IMVT
$3.74B
| – | – |
-25,924
|
|
||
102
Medpace
MEDP
$16.8B
| – | – |
-3,800
|
|
||
103
Merck
MRK
$220B
| – | – |
-33,000
|
|
||
104
Vir Biotechnology
VIR
$860M
| – | – |
-200,000
|
|
||
105
Zimmer Biomet
ZBH
$20.4B
| – | – |
-87,250
|
|